How EZHIP and the K27M change gene-silencing in childhood brain tumors
Understanding the regulation of PRC2 activity by EZHIP and the K27M oncohistone in pediatric gliomas
Researchers are looking at how two molecules, EZHIP and the K27M histone change, alter a gene-silencing system in pediatric glioma cells to better understand what drives these childhood brain tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-11247060 on NIH RePORTER |
What this research studies
From my perspective as someone affected by these tumors, the team will use biochemical experiments, genetic models, and genome-wide analyses to see how EZHIP and K27M change the activity and targeting of the PRC2 protein complex. They will study why some gene-silencing marks remain at important gene promoters in these tumors and how that supports tumor growth. The group will combine lab-based binding and enzyme assays with genetic manipulation and sequencing of tumor-related DNA regions to map the mechanism. Their work aims to pinpoint how PRC2 is misdirected so future treatments can target that process.
Who could benefit from this research
Good fit: Children or adolescents with K27M-mutant or EZHIP-associated gliomas, or families interested in contributing tumor samples or clinical data for research, would be the most relevant participants.
Not a fit: Patients with unrelated adult brain tumors or cancers that do not involve EZHIP or K27M alterations are unlikely to benefit directly from this specific research.
Why it matters
Potential benefit: If successful, this work could reveal new molecular targets or strategies to reverse harmful gene-silencing changes and ultimately lead to better treatments for pediatric gliomas.
How similar studies have performed: Previous research has shown that K27M and EZHIP alter PRC2 and reduce H3K27 methylation in these tumors, but the detailed mechanisms and their role in maintaining tumor growth are still being worked out.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Lewis, Peter W — University of Wisconsin-Madison
- Study coordinator: Lewis, Peter W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.